M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Management of a sporadic malignant subfrontal peripheral nerve sheath tumor.
Rene O. Sanchez-Mejia,Diep N. Pham,Michael D. Prados,Tarik Tihan,Soonmee Cha,Ivan H. El-Sayed,Michael W. McDermott +6 more
TL;DR: This case shows that these rare lesions can present as a malignant variant and thus require aggressive surgical and postoperative management to provide long-term tumor control.
Journal ArticleDOI
Stereotaxic interstitial iodine-125 “boost” in the initial management of malignant gliomas
Philip H. Gutin,William M. Wara,David B. Larson,Steven A. Leibel,Michael D. Prados,V. A. Levin,Patricia Sneed,Keith A. Weaver,Pamela Silver,Kathleen R. Lamborn,T.L. Phillips +10 more
TL;DR: It is concluded that for selected patients with GM, but not NGM, an interstitial eboostw is an advantage, and a trial integrating hyperthermia and brachytherapy into the adjuvant treatment of GM is being designed.
Journal ArticleDOI
Stereotaxic I-125 brain implants for malignant gliomas
Cindy O. Scharfen,Patricia Sneed,William M. Wara,M.D. Larson,T.L. Phillips,Keith A. Weaver,Michael D. Prados,Philip H. Gutin +7 more
Journal ArticleDOI
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort
Maria Vassilakopoulou,Maria Vassilakopoulou,Minhee Won,Walter J. Curran,Luis Souhami,Michael D. Prados,Corey J. Langer,David L. Rimm,Jason A. Hanna,Jason A. Hanna,Veronique Neumeister,Edward Melian,Aidnag Z. Diaz,James N Atkins,Lydia Komarnicky,Christopher J. Schultz,Steven P. Howard,Peixin Zhang,Adam P. Dicker,Jonathan P.S. Knisely +19 more
TL;DR: In this article, the authors investigated the prognostic significance of a panel of diverse cellular molecular markers of tumor formation and growth in an annotated glioblastoma tissue microarray (TMA).
Journal ArticleDOI
LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
Sabine Mueller,Mariam Aboian,Kellie J. Nazemi,Karen Gauvain,Janet M. Yoon,Jane E. Minturn,Sarah Leary,Mohamed S. AbdelBaki,Stewart Goldman,Jennifer D. Elster,Adam C. Resnick,Annette M. Molinaro,Joanna J. Phillips,Michael D. Prados,Daphne A. Haas-Kogan +14 more
TL;DR: Everolimus is well tolerated and active in a subset of pLGGs and ongoing analyses will assess predictive biomarkers of response and will be reported at the meeting.